-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Qilu Pharmaceutical has entered the administrative examination and approval stage with generic 3 types of Aprinast tablets.
Source: official website of the State Drug Administration
Apemilast (apmilast/apmilast) is a new oral, small molecule phosphodiesterase 4 (PDE-4) inhibitor developed by New Base (acquired by Amgen), which is dose-dependent Sexually inhibits the release of tumor necrosis factor (TNF)-α from human synovial cells
In addition to apremilast, the PDE-4 inhibitors currently on the market worldwide also include cliborrol, doxofylline, roflumilast, etc.
Production status of Apster tablets
Source: Mi Nei Net Consistency Evaluation Database
Amgen’s Apster tablets were approved for import in August 2021.
Qilu approved products since 2021
Source: Meinenet MED2.
According to data from Minai.
Sales of 3 first generic drugs in Chinese public medical institutions and physical pharmacies in cities in China (unit: 10,000 yuan)
Source: Mi Nei Net Database
The 3 first generic drugs are rasagiline mesylate, metformin vildagliptin tablets and trifluridine tepipyrimine tablets.
Source: Mi Nei.
Source: Mi Nei.
com database, official website of the State Drug Administration, etc.